scholarly journals Recent advancement in cancer detection using machine learning: Systematic survey of decades, comparisons and challenges

2020 ◽  
Vol 13 (9) ◽  
pp. 1274-1289 ◽  
Author(s):  
Tanzila Saba
Life ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 638
Author(s):  
Linjing Liu ◽  
Xingjian Chen ◽  
Olutomilayo Olayemi Petinrin ◽  
Weitong Zhang ◽  
Saifur Rahaman ◽  
...  

With the advances of liquid biopsy technology, there is increasing evidence that body fluid such as blood, urine, and saliva could harbor the potential biomarkers associated with tumor origin. Traditional correlation analysis methods are no longer sufficient to capture the high-resolution complex relationships between biomarkers and cancer subtype heterogeneity. To address the challenge, researchers proposed machine learning techniques with liquid biopsy data to explore the essence of tumor origin together. In this survey, we review the machine learning protocols and provide corresponding code demos for the approaches mentioned. We discuss algorithmic principles and frameworks extensively developed to reveal cancer mechanisms and consider the future prospects in biomarker exploration and cancer diagnostics.


2021 ◽  
Author(s):  
Lin Huang ◽  
Kun Qian

Abstract Early cancer detection greatly increases the chances for successful treatment, but available diagnostics for some tumours, including lung adenocarcinoma (LA), are limited. An ideal early-stage diagnosis of LA for large-scale clinical use must address quick detection, low invasiveness, and high performance. Here, we conduct machine learning of serum metabolic patterns to detect early-stage LA. We extract direct metabolic patterns by the optimized ferric particle-assisted laser desorption/ionization mass spectrometry within 1 second using only 50 nL of serum. We define a metabolic range of 100-400 Da with 143 m/z features. We diagnose early-stage LA with sensitivity~70-90% and specificity~90-93% through the sparse regression machine learning of patterns. We identify a biomarker panel of seven metabolites and relevant pathways to distinguish early-stage LA from controls (p < 0.05). Our approach advances the design of metabolic analysis for early cancer detection and holds promise as an efficient test for low-cost rollout to clinics.


Sign in / Sign up

Export Citation Format

Share Document